CHILDREN'S HOSPITAL LOS ANGELES

Healthcare leaders focus on improving patient care through innovation, accessibility, and patient-centered strategies, emphasizing technology, workforce resilience, health equity, and care model reimagination. Key priorities include enhancing access, leveraging AI, patient-centered care, workforce resilience, high reliability, health equity, patient experience, care delivery models, data analytics, value-based care, and transparency.

Dr. Bianca Edison advises parents on when to seek medical attention for child injuries, emphasizing symptoms like severe crankiness, multiple vomiting episodes, slurred speech, and different pupil sizes. Head injuries from significant falls, eye injuries, mouth/tooth injuries, and fractures require immediate medical care. Knowing these signs can help parents react quickly and effectively.

NIH's myeloMATCH trial tests new treatment combinations for AML and MDS based on genetic changes, aiming to accelerate tailored treatments. Participants undergo rapid genetic testing to match with appropriate substudies or standard treatment, with further testing as disease reduces. The trial aims to enroll thousands and refine assays to understand treatment resistance.

NIH launches precision medicine trial, myeloMATCH, to test new treatment combinations for AML and MDS, aiming to accelerate tailored treatments through rapid genetic testing and targeted drug combinations.

Minority teens treated at pediatric trauma centers are more likely to be drug and alcohol tested than white peers, according to a UCLA-led study. Black, Hispanic, and American Indian teens faced higher odds of screening, with girls and Medicaid-insured teens also more likely to be tested. The study calls for stricter guidelines and universal screening protocols to ensure equitable care.

MRE and TE may not accurately predict high-grade fibrosis in pediatric MASLD compared to liver biopsy, with MRE slightly outperforming TE in AUROC. MASLD affects up to 38% of obese children in the U.S. and can lead to cirrhosis if untreated. A study at Children's Hospital Los Angeles found both MRE and TE lacking in precision for fibrosis prediction, necessitating further research with larger, diverse samples.

A study shows liraglutide, combined with diet and exercise, is safe and effective for kids aged 6-11, reducing BMI and improving health markers. Novo Nordisk seeks US approval for this age group, aiming to treat common childhood obesity. Side effects, mainly gastrointestinal, were common but mostly mild. Experts emphasize careful consideration of risks and long-term effects.